ASCO 2021 | Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockade
Nadia Harbeck, MD, PhD, Ludwig-Maximilians-University of Munich, Munich, Germany, discusses the updates in the ADAPT-HR-/HER2+ clinical trial which aimed to compare pathological complete response (pCR) in patients who received pertuzumab/trastuzumab along with paclitaxel and patients who responded early towards pertuzumab/trastuzumab. Prof. Harbeck presents the first survival data from this clinical trial and highlights the superiority of pCR in patients who received pertuzumab/trastuzumab along with paclitaxel. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Nadia Harbeck, MD, PhD, has received honoraria for lectures and/or consulting from Astra Zeneca, Daiichi-Sankyo, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, and Seattle Genetics. Prof. Harbeck is also a co-director of the West German Study Group (WSG)
